Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hopefully a PR about the 10 working models comes out soon. They should be ready any time now. Once those are out the FDA process can begin. I believe once those models are out would be great time to have the published results out as well. Bring the models and 10 years of testing to trade shows will get peoples attention.
Very nice! Hopefully we can here of a European distributor next
ALXA
10K http://ih.advfn.com/p.php?pid=nmona&article=51587407
The number of outstanding shares of the Registrant’s common stock as of March 1, 2012 was 116,136,338.
The FDA takes an advisory committee’s advice into consideration as part of its review of an NDA, but is not bound by an advisory committee's recommendations. After reviewing and discussing the ADASUVE data and the FDA proposed REMS, the committee voted on the following additional questions:
Does the committee conclude that ADASUVE (loxapine) inhalation powder has been shown to be effective as a treatment for agitation in patients with schizophrenia or bipolar mania? The resulting vote was: 17/1/0 (yes/no/abstain).
Does the committee conclude that ADASUVE (loxapine) inhalation powder has been shown to be acceptably safe for use as a treatment for agitation in patients with schizophrenia or bipolar mania:
a. When used in conjunction with the REMS proposed by the sponsor? The resulting vote was: 1/17/0 (yes/no/abstain).
b. When used in conjunction with the REMS proposed by the FDA? The resulting vote was: 5/12/1 (yes/no/abstain).
Does the committee conclude that ADASUVE (loxapine) inhalation powder would be acceptably safe for use as a single dose in 24 hours as a treatment for agitation in patients with schizophrenia or bipolar mania when used in conjunction with the REMS proposed by FDA? The resulting vote was: 11/5/2 (yes/no/abstain).
Our Pipeline
Alexza Commercial Rights
ADASUVE Loxapine
Agitation in adults with schizophrenia or bipolar disorder
NDA resubmitted and a scheduled PDUFA date of May 4, 2012.
MAA accepted for assessment by the EMA on October 26, 2011.
Our product candidates not in active development are:
AZ-104 ( Staccato loxapine, low-dose). AZ-104, a lower-dose version of ADASUVE, is designed for the treatment of patients suffering from acute migraine headaches. AZ-104 has completed a Phase 1 clinical trial in healthy subjects and two Phase 2 clinical trials in patients with migraine headaches.
AZ-002 (Staccato alprazolam). AZ-002 has completed a Phase 1 clinical trial in healthy subjects and a Phase 2a proof-of-concept clinical trial in panic disorder patients for the treatment of panic attacks, an indication we are not planning to pursue. However, given the safety profile, the successful and reproducible delivery of alprazolam, and the IV-like pharmacological effect demonstrated to date, we may in the future assess AZ-002 for other possible indications and renewed clinical development.
AZ-003 ( Staccato fentanyl). We have completed and announced positive results from a Phase 1 clinical trial of AZ-003 in opioid-naïve healthy subjects. This product candidate is designed for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes.
Other than those licensed to Grupo Ferrer for our ADASUVE product and Cypress for our Staccato nicotine product candidate, we have retained all rights to our product candidates and the Staccato system. We intend to capitalize on our internal resources to develop certain product candidates and to identify routes to utilize external resources to develop and commercialize other product candidates.
http://ih.advfn.com/p.php?pid=nmona&article=51528677
On March 5, 2012, Alexza Pharmaceuticals, Inc. (“Alexza”) and Grupo Ferrer Internacional, S.A. (“Ferrer”) entered into an amendment (the “Amendment”) to the Collaboration, License and Supply Agreement (the “Agreement”) dated as of October 5, 2011. Pursuant to the Amendment, Ferrer and Alexza have agreed to eliminate a future potential milestone payment under the Agreement effective upon the purchase of 2,419,355 shares of Alexza common stock by Ferrer in a private placement at a purchase price of $1.24 per share. The purchase of the common stock by Ferrer will be subject to customary closing conditions and is expected to occur not later than March 15, 2012 pursuant to a stock purchase agreement (the “Stock Purchase Agreement”). The Amendment also provides that during 2012 up to an additional $8 million of Alexza common stock may be purchased by Ferrer, upon a request by Alexza and subject to acceptance by Ferrer, in exchange for the elimination of specified additional milestone payments at a price per share that will be a premium to the market price on the date of purchase
http://ih.advfn.com/p.php?pid=nmona&article=51244104
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), or the Company, today announced that it has priced its previously announced underwritten public offering of 44,000,000 shares of common stock and warrants to purchase 44,000,000 shares of common stock. The common stock and warrants will be issued separately, but will be sold in combination in the offering, with a warrant to purchase one share of common stock for each share of common stock sold. The price to the public for each share and related warrant is $0.50, for an aggregate offering amount of approximately $22 million.
Some upward movement after hours today. Going through the 10k now. I noticed tomorrow is the last day for grupo ferrer to purchase 2.4 mil shares @ 1.24 price. Will post some notes and links later.
Anyone watching ALXA? Could be an interesting play
Hey now. The drug tester handled his sample wrong. Lol. Pac Man is a demon. Floyd is just a butterfly in a moth outfit
MMA is taking some of the thunder but definitely nothing like a great boxing match. Do need another heavy weight to step up.
Same here, so cant complain. Last year was the year of tytanic. This year much better with the year of the PS underway.
Manny is just lethal and Floyd knows it with his BS antics. I just hope this doesn't go down as one of the greatest fights that never happened.
I always enjoyed watching Floyd in the ring but outside of it, is a turn off. This fight could reenergize boxing and needs to happen
Throwing salt in my wound with TLON. Brought that up on 1/5 on the board. It was mid 40s at that point. My damn watch list for '12 is killing my actual positions. Lol.
That's jacked up. Yeah he never seemed to shy away from the spotlight and typically those are the ones that go down hard. Speaking of which, this Pac Man/ Floyd fight needs to finalize. Like to see Floyd get shut up.
Yeah I hear that. I am probably going to regret getting rid of some TDGI but mid 50s VRSEF was to good to pass up, in my opinion.
It was pretty crazy feeling tremors here in SW part of Ohio. From what I read NY, PA, MD, and DC felt it to. Certainly changes the direction to recover natural gas in these parts.
I remember all three of there fights. Back in the day boxing was boxing not some bogus show like now. I was a big fan of bad intentions Taylor. Remember him taking out pavlik in the olympics. Very few saw their first pro fight with pavlik winning. Great call on your part
VRSEF- Old interview but a rehash what we might be expecting this month.
http://www.cantechletter.com/2011/10/cantech-letter-interviews-thomas-braun-of-verisante-technology/
We will start pre-marketing by going to dermatology and medical device conferences and trade shows. A lot of people simply won’t buy it until they can get a live demonstration, we expect that by March we will have fully functioning models from Starfish that we can take to trade shows and demonstrate for delivery in June. We should be generating revenue starting in eight months. Before the end of this year we will have seven fully functioning prototypes that we will send out to leading clinics in Australia, the UK, to Cambridge, and in the United Sates. We’ll use this to collect tons of data and then use that data to try and get FDA approval.
The February offering was $.25 cents a unit and the warrants had an exercise price of $.30 cents and those have all been exercised. Now it’s just the $.50 cent warrants from April that are out there.
Good point. I'm in cincy and here news on this from time to time. Ohio is on a major fault line and seems that drilling/fluids may be causing some tremors. Local residents are not to happy from what I hear either.
http://www.huffingtonpost.com/mobileweb/2012/03/09/ohio-fracking-earthquakes-cause-determined_n_1334808.html
MDXG- penny warrants on the table. Lets see how long before they are sold off.
No news and a combination of warrants being converted is what I think is going on.
VRSEF- been wondering the same thing. All I can find is, it is currently in the peer review process. Any kind of update would be great at this point.
I hear ya. I should have put the ticker symbol like MA stated. Either VRSEF or ADXS is a buy at these prices, in my opinion, and that is coming from a trader and not a holder.
True. Did forget. Can't complain though, the others were at .60.
MDXG- if you are still watching keep an eye on it this week. Looking to see if I can get some at 1.10 or better. Some downward pressure on this, this week.
ADXS- these amendments are starting to get on my nerves. It is what it is though. Agree, the recent news has been very positive and only a matter of time for the PPS to rebound.
I was happy. Got 170 of them. I am a high roller! Lol.
Wow. This post reminds me of inception. Somebody needs to make sure Stills woke up and came back all the way! Great post
Wish I had a ST account. Sounds like fun. I think Investopedia has something like this to.
HBRM- noticed this the other day. A/S raised on 2/23.
http://www.otcmarkets.com/financialReportViewer?symbol=HBRM&id=74147
I do not believe you are mistaken. The 12.8 mil, from the 2/7 filing, are included in the updated POS AM filing(2/29) of 24 mil.
MDXG
'11 year end results CC
http://mimedx.com/investors/
'11 year end results
http://www.prnewswire.com/news-releases/mimedx-group-announces-2011-results-140690723.html
The Company recorded record revenue for the year ended December 31, 2011, with revenue of $7.8 million, a tenfold increase over 2010 full year revenue of $789,000. The Company recorded a net loss of $10.2 million, or $0.14 per diluted common share, for the year ended December 31, 2011, a $1.2 million improvement as compared to the net loss of $11.4 million, or $0.19 per diluted common share, recorded for the year ended December 31, 2010. The earnings before interest, taxes, depreciation, amortization and share based compensation (Adjusted EBITDA*) for the year ended December 31, 2011, were a loss of $6.3 million, a $2.0 million improvement as compared to the Adjusted EBITDA loss of $8.3 million for the year ended December 31, 2010.
ADXS
Filed Yesterday- resale of 24 mil shares
http://ih.advfn.com/p.php?pid=nmona&article=51424546
These shares represent approximately 8.5% of our currently outstanding shares of common stock (based on 284,552,554 shares of common stock outstanding as of February 23, 2012). These shares also represent approximately 4.95% of our currently outstanding shares of common stock (based on 487,806,186 shares of common stock outstanding as of February 23, 2012) on a fully diluted basis
Filed on 2/7/12- resale of 12.8 mil shares
http://ih.advfn.com/p.php?pid=nmona&article=51078767
These shares represent approximately 4.8% of our currently outstanding shares of common stock (based on 269,425,632 shares of common stock outstanding as of January 9, 2012). These shares also represent approximately 2.7% of our currently outstanding shares of common stock (based on 486,728,991 shares of common stock outstanding as of January 9, 2012) on a fully diluted basis.
15 mil increase in O/S from 1/9-2/23. Once this stops, hopefully it gets it legs back under them.
Very nice. Punch through those 24s and this could get interesting.
TDGI- not to shabby for one movie. Thanks for the dig up.
VRSEF- hopefully the year end will be out in the next couple weeks. Maybe something in there that can shed some light. Not a whole lot of news out there right now. I did see that Starfish is attending the Opal Medical Device Summit march 5th. That is about all I could find new recently.
VRSEF- anyone seen a possible year end report date? Looking at previous filing dates, it seems they try to get that out 2 months after the quarter ends.
Yeah that was another odd day. Hit 60 and then dropped to the 40s. You never know what you get with those FDA approval plays.
IGXT- good company. Actually had it as my WC here. Have not followed it recently since I got out in dec. Kicking myself for that. Would have been up .25 now. I do like there approach of making approved drugs better. Helps speed up there approval process and keeps cost lower.
VRSEF
Attending the American Academy of Dermatology 70th Annual Meeting. 3/16-3/20.
http://show.aad.org/annual12/EC/forms/attendee/indexTab.aspx
If you can get under .15, great buy. I see they sent out another prospectus today.
ADXS- Sorry about that MA. Should have put the S1.
http://ih.advfn.com/p.php?pid=nmona&article=50930759
Conversion of outstanding Notes and exercise of Warrants could significantly dilute the ownership interests of existing stockholders.
The conversion or exercise of some or all of our outstanding Notes and Warrants could significantly dilute the ownership interests of existing stockholders. As of January 9, 2013, there were 8,215,690 shares of our common stock issuable upon conversion of the Notes, which have a conversion price of $0.15 per share, and 4,682,940 shares of our common stock issuable upon the exercise of the Warrants, which have an exercise price of $0.15 per share. Any sales in the public market of the common stock issuable upon such conversion or exercise could adversely affect prevailing market prices of our common stock. Moreover, the existence of the Notes may encourage short selling by market participants because the conversion of such Notes could be used to satisfy short positions, or the anticipated conversion of such Notes into shares of our common stock could depress the price of our common stock.
As a result of anti-dilution protection provisions contained in certain of our outstanding warrants, we (i) reduced the exercise price from $0.20 to $0.17 per share in January 2010 and further reduced the exercise price from $0.17 to $0.15 per share in September 2010 with respect to substantially all the warrants to purchase shares of our common stock and (ii) correspondingly adjusted the amount of warrant shares issuable such that approximately 11.4 million additional warrant shares are issuable related to the January 2010 repricing and approximately 10.4 million additional warrant shares are issuable related to the September 2010 repricing. As of October 31, 2011, approximately 108 million warrant shares are currently exercisable at $0.15 per share.
GFDV- I hear ya there. Not sure what to think either. They have two projects currently, as stated per there web-site.
http://www.genfd.com/projects.htm
ADXS- http://ih.advfn.com/p.php?pid=nmona&article=50577903
A 130k float and less then 5 mil O/S. That is crazy. Good luck getting shares! Not a whole lot of info on there web-site though.
It will certainly be interesting to see how the full year report comes out. They are still waiting on FDA approval for there CollaFix. Was CE approved earlier.
ADXS- I was going off of Harley's post on 1/27. He pulled up some info off of the Prospectus. Post 7677.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=71420026
This prospectus relates to the resale by the selling stockholders of up to 12,898,630 shares of our common stock, including (i) 8,215,690 shares of common stock issuable upon conversion of the principal amount of Notes and (ii) 4,682,940 shares of common stock underlying the Warrants, which were issued in connection with our Series C convertible notes financing.
You are not the only one headscratching, but atleast this makes sense with the recent bottleneck at .15.